Note: no compound ID or specific hit context was given, so I've treated "your MEK1/2 hit" as the target pair **MAP2K1 (MEK1, UniProt Q02750) / MAP2K2 (MEK2, UniProt P36507)** — the canonical dual-specificity kinases in the RAS→RAF→MEK→ERK cascade — rather than a specific chemical series. If you're actually sitting on a compound against these, everything below on the target biology still applies; just swap in your own SAR/PK data.

## 1. Mechanism & disease links
MEK1/2 sit immediately downstream of RAF (BRAF/RAF1/ARAF) and phosphorylate ERK1/2 (Thr/Tyr in the TEY activation motif), the terminal kinases of the canonical MAPK proliferation/survival pathway. They're allosterically drugged (not ATP-competitive) — this is the mechanistic reason MEK is one of the few kinases with multiple approved non-ATP-site inhibitors.

- **Cancer**: Somatic activating mutations reported in melanoma, lung cancer, and leukemia/lymphoma; also the dominant acquired-resistance node after BRAF inhibitor therapy (e.g., MEK2-C125S, BRAF/NRAS reactivation) ([Nature Communications](https://www.nature.com/articles/s41467-022-31690-w), [Mol Cancer Res](https://aacrjournals.org/mcr/article/15/10/1431/266318/BRAF-inhibitor-Associated-MEK-Mutations-Increase)).
- **RASopathies**: Germline MAP2K1/MAP2K2 mutations cause **Cardiofaciocutaneous syndrome (CFC3/CFC4)** — ~25% of CFC cases — via constitutive MAPK hyperactivation, distinct in severity/spectrum from the cancer-associated alleles ([GeneCards](https://www.genecards.org/card/MAP2K1), [Nat Commun mutant-signature paper](https://www.nature.com/articles/s41467-022-31690-w), [UniProt P36507](https://www.uniprot.org/uniprot/P36507)).
- Bottom line: this is a validated, clinically precedented oncology node (4 approved MEK inhibitors) with a well-characterized germline liability class — no mechanistic surprises to flag.

## 2. Domains & PTMs
| Feature | MEK1 (Q02750) | MEK2 (P36507) |
|---|---|---|
| Kinase domain | 68–361 | 72–369 |
| N-term disordered/regulatory | 1–27 | — |
| RAF1-binding region | 270–307 | 286–310 (disordered) |
| Activating phospho-sites | Ser218, Ser222 (by BRAF/RAF1) | Ser222, Ser226 |
| Other regulatory phospho | Thr286, Thr292 (by ERK, feedback), Ser298 (by PAK) | Ser23, Ser293/295/306, Thr394/396 |
| Notable PTM | Acetylation of the S218/S222-equivalent region by *Yersinia* YopJ blocks activation (pathogen immune-evasion mechanism, useful mechanistic precedent for allosteric shutoff) | Same YopJ acetylation mechanism at Ser222/Ser226 |

Source: [UniProt Q02750](https://rest.uniprot.org/uniprotkb/Q02750.txt), [UniProt P36507](https://rest.uniprot.org/uniprotkb/P36507.txt).

Practical read: S218/S222 (MEK1) phospho-status is your standard target-engagement biomarker (phospho-MEK/phospho-ERK Western or MSD assay) if you need a PD readout.

## 3. Subcellular localization
Predominantly **cytoplasmic**, with peripheral membrane association (MEK2 localization is regulated via KSR1 scaffolding). MEK1 additionally shows **cytoskeletal/centrosomal** pools — at microtubule-organizing centers/centrosomes in interphase, midzone during anaphase — consistent with reported roles beyond canonical ERK signaling (mitotic regulation). Not nuclear-resident at steady state, though it shuttles ERK into the nucleus upon activation. ([UniProt Q02750](https://rest.uniprot.org/uniprotkb/Q02750.txt), [UniProt P36507](https://rest.uniprot.org/uniprotkb/P36507.txt))

## 4. Structural confidence
Extensive crystallography exists for the kinase domain (e.g., PDB 3EQB, 3EQC, 3EQF — MEK1 with MgATP/inhibitor complexes) ([RCSB 3EQB](https://www.rcsb.org/structure/3EQB)). Given this domain is well-resolved experimentally, AlphaFold's per-region confidence for MEK1/2 follows the expected pattern for a kinase with solved catalytic domain + flexible termini:
- **High confidence (pLDDT likely >90)**: kinase domain core, ~68–361 (MEK1) / 72–369 (MEK2), including the ATP pocket and adjacent allosteric pocket that all approved MEK inhibitors occupy.
- **Lower confidence/disordered**: N-terminal negative-regulatory segment (~1–27) and the C-terminal/activation-loop-adjacent proline-rich linker region — consistent with UniProt's own disorder annotation for these stretches.
I could not pull the exact per-residue pLDDT trace live (AlphaFold DB's page is JS-rendered and didn't return numeric data to the fetch); if you need exact values, pull the PAE/pLDDT JSON directly from `alphafold.ebi.ac.uk/files/AF-Q02750-F1-model_v4.pdb` header or the EBI API rather than the HTML page. Practically: the domain that matters for drug design (kinase + allosteric pocket) is high-confidence and cross-validated by multiple crystal structures, so you can trust docking/design work there.

## 5. CRISPR essentiality (DepMap)
MAP2K1 scores among genes with strong, broad dependency — it's flagged as a top MAPK-pathway dependency alongside EGFR/ERBB2/BRAF/ERBB4 in DepMap's pan-cancer biomarker analyses, and the **MAP2K1–MAP2K2 pair is the only paralog pair identified as mutually synthetic-lethal across essentially all cell lines tested** (i.e., cells tolerate loss of one paralog but not both) ([bioRxiv paralog dependency map](https://www.biorxiv.org/content/10.64898/2026.01.19.700065v1.full), [SuperDendrix/Cell Genomics](https://www.cell.com/cell-genomics/pdf/S2666-979X(22)00016-7.pdf)). This is a double-edged fact for drug hunting: single-paralog knockdown may look weakly essential in DepMap's individual Chronos scores while the real vulnerability is paralog-redundant — worth checking whether your hit hits both MEK1 and MEK2, since a MEK1-only tool compound could underestimate cellular potency due to MEK2 compensation. I couldn't retrieve MAP2K1's exact numeric Chronos gene-effect score from the live portal (JS-rendered, no API pull performed here) — pull it directly from `depmap.org/portal/gene/MAP2K1?tab=characterization` for a precise per-lineage plot before you commit resources.

## 6. Drug sensitivity
Four MEK1/2 inhibitors are already approved/clinical (trametinib, selumetinib/AZD6244, cobimetinib, binimetinib), all allosteric, non-ATP-competitive.
- **Trametinib**: IC50 0.7–0.9 nM vs MEK1/2, highly selective (no activity across >98 other kinases tested); clinical ORR ~25% in BRAF-mutant melanoma naive to BRAF inhibitors, but essentially no activity post-BRAFi resistance ([JCO phase II](https://ascopubs.org/doi/abs/10.1200/JCO.2012.43.5966)).
- **Selumetinib (AZD6244)**: enzyme IC50 10–14 nM; in cell panels, **BRAF V600E lines are exquisitely sensitive (<100 nM)** due to high baseline phospho-MEK and loss of ERK→RAF negative feedback ([AACR Cancer Research](https://dx.doi.org/10.1158/0008-5472.CAN-08-1430)).
- **GDSC/CCLE pharmacogenomics**: PD0325901 and selumetinib show the strongest cluster-associated sensitivity signal in melanoma (SKCM) lines specifically, tracking with BRAF mutation status ([Scientific Reports](https://www.nature.com/articles/s41598-017-14770-6)).
- **Biomarker caveat**: outside BRAF/NRAS mutation status, no other biomarker reliably predicts MEK1/2-inhibitor response — so if your hit's differentiation story depends on a novel biomarker hypothesis, that's still an open, unmet need in the field, not table stakes.

## Net take
MEK1/2 is a mechanistically clean, structurally tractable, genetically validated dependency in RAS/RAF-mutant cancers with real clinical precedent — but it's also a crowded, well-drugged space with a known resistance-prone biology (paralog compensation, feedback reactivation) and no biomarker edge beyond BRAF/NRAS. The decision-relevant question before you sink more time in is differentiation: is your hit dual MEK1/MEK2, does it survive the paralog redundancy DepMap flags, and does it offer anything (selectivity, PK, combination angle, resistance-mutant coverage) beyond the four approved drugs — because on pure "is this a real, essential, druggable target," the answer is unambiguously yes.